Pharmaceutical companies; creating the Oklahoma Medicine Injury Justice Act; providing for civil and criminal liability. Effective date. Emergency.
SB 801, the Oklahoma Medicine Injury Justice Act, would create a new state-law framework aimed at holding pharmaceutical companies directly accountable in Oklahoma courts for harm caused by their products. The bill declares legislative findings emphasizing state sovereignty, the right to a remedy, and the view that federal immunity laws can prevent injured Oklahomans from obtaining adequate relief. It defines “fraud” and “gross negligence,” and authorizes direct civil liability for compensatory damages, noneconomic damages, and punitive damages when gross negligence or fraud is shown.
The bill also goes beyond civil liability by stating that pharmaceutical companies may be criminally prosecuted for gross negligence, fraudulent concealment, reckless disregard for safety, or intentional harm. It expressly says that certain federal immunity statutes, including the National Childhood Vaccine Injury Act, the PREP Act, the Project BioShield Act, and the Defense Production Act, would not apply to claims brought in Oklahoma state courts. The measure further requires that claims be heard in Oklahoma state court, without arbitration or other limits on access to justice, and provides that conflicting laws yield to the act. If enacted, it would be codified primarily in Title 63 of the Oklahoma Statutes.
The bill’s impact would be significant for pharmaceutical manufacturers and for the state’s civil and criminal justice systems. It would attempt to override or limit the practical effect of federal immunity protections in state litigation, expand available damages, and create a state-law basis for criminal prosecution tied to product-related harm. It also asserts Oklahoma jurisdiction and due process protections for injured citizens, signaling an effort to strengthen state-court remedies for drug- and vaccine-related claims.
There is no recorded committee transcript or vote history in the provided materials, so the general sentiment can only be inferred from the bill text and procedural posture. The bill’s sponsor appears strongly supportive of aggressive accountability for pharmaceutical companies, framing the measure as necessary to protect public health and constitutional rights. Its referral to Judiciary suggests it would likely receive close legal scrutiny because of its broad assertions about state authority and federal preemption.
The main points of contention are likely to be the bill’s attempt to negate federal immunity statutes, its assertion of state jurisdiction over claims that may be federally regulated, and its authorization of criminal prosecution for conduct traditionally handled through civil liability or federal enforcement. Pharmaceutical companies, federal-law proponents, and likely some legal analysts would view the measure as potentially conflicting with federal law and constitutional limits, while supporters would emphasize state sovereignty, access to courts, and remedies for injured patients.
If enacted, SB 801 would create new uncodified findings and add new sections to Title 63 of the Oklahoma Statutes establishing direct civil liability and possible criminal exposure for pharmaceutical companies. It would purport to make federal immunity provisions inapplicable in Oklahoma state court claims, require state-court adjudication without arbitration limits, and give the act priority over conflicting laws. The bill would therefore materially alter the legal landscape for pharmaceutical injury claims in Oklahoma by expanding remedies and attempting to limit defenses based on federal immunity.
No committee discussion or vote record is provided, so there is no documented bipartisan sentiment to summarize. The bill text itself reflects a strongly pro-plaintiff, anti-immunity posture, with the sponsor framing the measure as a protection of citizens, state sovereignty, and constitutional rights. Procedurally, the bill had been second-read and referred to Judiciary as of February 4, 2025, indicating it was still under legal review rather than having advanced on recorded votes.
The most notable controversy is the bill’s effort to override federal immunity statutes such as the PREP Act and the National Childhood Vaccine Injury Act, which raises likely preemption and constitutional questions. Another major point of contention is the bill’s authorization of criminal prosecution for pharmaceutical companies based on gross negligence, fraud, reckless disregard, or intentional harm, which is unusual and likely to draw scrutiny over standards of proof and enforcement authority. Supporters would focus on accountability and access to remedies, while opponents would likely argue that the bill conflicts with federal law, creates legal uncertainty, and could deter pharmaceutical activity or emergency-response participation.